The specific aims of the Heartland Cancer Research NCORP are to: (1)To be the primary vector for delivering;implementing, and executing NCI approved cancer treatment clinical trials to a large Midwestern rural and urban population; (2) To be the primary vector for delivering, implementing, and executing NCI approved cancer prevention, screening and control clinical trials to a large Midwestern rural and urban population; (3) To be the primary vector for delivering, implementing, and executing NCI approved Cancer Care Delivery Research clinical trials to a large Midwestern rural and urban population; (4) Enhance Midwestern cancer care by implementing a region-wide high standard of multidisciplinary integrated cancer care delivery; (5) Improve the education and outreach to all healthcare providers across rural and urban Illinois and Missouri regarding cancer clinical trials and incorporation of new research findings into daily patient care; (6) Improve cancer prevention, treatment, and survivorship education for healthcare professionals throughout Illinois and Missouri; (7) Perform breakthrough research in methods to improve the efficacy, efficiency, and cost effectiveness of cancer care delivery for a large region across Illinois and Missouri; (8) Reach out to underserved and vulnerable populations across Illinois and Missouri to improve access to cancer clinical trials, state of the art care, and cancer prevention and earl detection strategies; (9) Coordinate with local and state agencies to leverage resources to improve state wide cancer education regarding cancer prevention, early detection, treatment and clinical trials; (10) Continue to explore best practices for improving the productivity of Heartland NCORP within an environment of limited resources; (11) Continue to recruit, train, and support new investigators who share the vision and embrace the objectives of the Heartland NCORP

Public Health Relevance

The Heartland Cancer Research NCORP (Heartland NCORP) will be the premier community cancer research organization of the states of Illinois and Missouri by providing state of the art cancer clinical trials, cancer care delivery research, interdisciplinary cancer treatment planning, and coordinated biomarker driven research throughout our service region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
1UG1CA189830-01
Application #
8790489
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Xie, Heng
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$2,520,862
Indirect Cost
$226,227
Name
Decatur Memorial Hospital
Department
Type
DUNS #
046584991
City
Decatur
State
IL
Country
United States
Zip Code
62526
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Martin, P; Jung, S-H; Pitcher, B et al. (2017) A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 28:2806-2812
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Wakelee, Heather A; Dahlberg, Suzanne E; Keller, Steven M et al. (2017) Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 18:1610-1623

Showing the most recent 10 out of 30 publications